$0.3432
At close: Apr 22, 3:45 PM EDT
$0.3050
-0.04-11.13%
After Hours: Apr 8, 8:07 AM EDT
Comments
Loading...
Panbela Therapeutics Earnings Estimates, EPS & Revenue | OTC:PBLA | Benzinga
Panbela Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Nov 14
EPS
$-1.480
Quarterly Revenue
$0.00
Annual Revenue
(as of Sep 30)
(as of Sep 30)
–
Analyze the earnings history of Panbela Therapeutics using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PBLA | Panbela Therapeutics | -$53.74 | — | -$1.48 | — | $0.00 | — | $0.00 | — | 11/14/2024 | Get Alert |
| PBLA | Panbela Therapeutics | -$159.15 | -$1.69 | -$1.47 | 13.02% | $0.00 | — | $0.00 | — | 08/13/2024 | Get Alert |
| PBLA | Panbela Therapeutics | -$19.50 | -$1.48 | -$2.28 | -54.05% | $0.00 | — | $0.00 | — | 05/15/2024 | Get Alert |
| PBLA | Panbela Therapeutics | -$170.40 | -$24.34 | -$65.90 | -170.75% | $0.00 | — | $0.00 | — | 03/26/2024 | Get Alert |
| PBLA | Panbela Therapeutics | -$252.00 | -$2.06 | -$2.42 | -17.43% | $0.00 | — | $0.00 | — | 11/09/2023 | Get Alert |
| PBLA | Panbela Therapeutics | -$1.81K | -$4.70 | -$7.95 | -69.15% | $0.00 | — | $0.00 | — | 08/10/2023 | Get Alert |
| PBLA | Panbela Therapeutics | -$324.00 | -$16.20 | -$19.50 | -20.37% | $0.00 | — | $0.00 | — | 05/04/2023 | Get Alert |
| PBLA | Panbela Therapeutics | -$312.00 | -$111.00 | -$170.40 | -53.51% | $0.00 | — | $0.00 | — | 03/16/2023 | Get Alert |
| PBLA | Panbela Therapeutics | -$192.00 | -$264.00 | -$252.00 | 4.55% | $0.00 | — | $0.00 | — | 11/10/2022 | Get Alert |
| PBLA | Panbela Therapeutics | -$264.00 | -$276.00 | -$1.81K | -556.52% | $0.00 | — | $0.00 | — | 08/15/2022 | Get Alert |
| PBLA | Panbela Therapeutics | -$276.00 | -$300.00 | -$324.00 | -8.00% | $0.00 | — | $0.00 | — | 05/12/2022 | Get Alert |
| PBLA | Panbela Therapeutics | -$108.00 | -$216.00 | -$312.00 | -44.44% | $0.00 | — | $0.00 | — | 03/24/2022 | Get Alert |
| PBLA | Panbela Therapeutics | -$252.00 | -$276.00 | -$192.00 | 30.43% | $0.00 | — | $0.00 | — | 11/10/2021 | Get Alert |
| PBLA | Panbela Therapeutics | — | -$216.00 | -$264.00 | -22.22% | — | — | $0.00 | — | 08/11/2021 | Get Alert |
| PBLA | Panbela Therapeutics | — | -$132.00 | -$276.00 | -109.09% | — | — | $0.00 | — | 05/12/2021 | Get Alert |
| PBLA | Panbela Therapeutics | — | — | -$108.00 | — | — | — | $0.00 | — | 03/26/2021 | Get Alert |
| PBLA | Panbela Therapeutics | — | -$144.00 | -$252.00 | -75.00% | — | — | $0.00 | — | 11/12/2020 | Get Alert |
Panbela Therapeutics (PBLA) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | 2024-08-13 | $-1.47 | $-1.69 | 13.0 % |
| Q1 | 2024-05-15 | $-2.28 | $-1.48 | -54.0 % |
| Q4 | 2024-03-26 | $-65.90 | $-24.34 | -170.8 % |
| Q3 | 2023-11-09 | $-2.42 | $-2.06 | -17.4 % |
Panbela Therapeutics (PBLA) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
FAQ
When is Panbela Therapeutics (OTCPK:PBLA) reporting earnings?
Panbela Therapeutics (PBLA) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3.
What were the latest earnings per share (EPS) for Panbela Therapeutics (OTCPK:PBLA)?
Panbela Therapeutics (PBLA) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3 and the Actual EPS was $-1.48, which missed the estimate of $0.00.
What were Panbela Therapeutics’s (OTCPK:PBLA) revenues?
Panbela Therapeutics (PBLA) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3 and the Actual Revenue was $0K, which hit the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.
